Compare DexCom, Inc. (DXCM) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard High Dividend Yield ETF — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Vanguard High Dividend Yield ETF trades at $158.56 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 3.2× DexCom, Inc.'s market cap, and Vanguard High Dividend Yield ETF is more actively traded (908,176 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| DXCM | VYM | |
|---|---|---|
Market Cap | $31.86B | $100.80B |
Volume | 3,607,070 | 908,176 |
Sector | Health | — |
52-Week High | $92.34 | $167.03 |
52-Week Low | $54.84 | $137.47 |
Typical Hold Time | 62 Days | 138 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
VYM trades at $157.45, down 0.58% with a bearish technical signal. The ETF shows neutral oscillators but bearish moving averages, with support at $157 and resistance at $158. Recent news highlights VYM's consistent dividend yield of 2.42% but notes performance lag versus peers like SCHD and IDV, which have outperformed year-to-date.
VYM faces competition from higher-yielding alternatives and exhibits vulnerability to dividend cuts in its holdings. The ETF's broad diversification provides stability, but investors may seek better returns elsewhere. Key risks include sector concentration and interest rate sensitivity affecting dividend appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
